This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Tvardi Therapeutics (TVRD) and Organigram Global (OGI)

Tipranks - Tipranks - Wed May 13, 4:12PM CDT

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Legend Biotech (LEGN), Tvardi Therapeutics (TVRD) and Organigram Global (OGI).

Claim 55% Off TipRanks

Legend Biotech (LEGN)

TD Cowen analyst Yaron Werber maintained a Hold rating on Legend Biotech today and set a price target of $29.00. The company’s shares closed last Tuesday at $28.26.

According to TipRanks.com, Werber is a 5-star analyst with an average return of 24.9% and a 60.0% success rate. Werber covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Terns Pharmaceuticals, and Ionis Pharmaceuticals. ;'>

Currently, the analyst consensus on Legend Biotech is a Strong Buy with an average price target of $57.16, a 132.1% upside from current levels. In a report issued on May 7, TipRanks – PerPlexity also reiterated a Hold rating on the stock with a $31.00 price target.

See the top stocks recommended by analysts >>

Tvardi Therapeutics (TVRD)

JonesTrading analyst Debanjana Chatterjee reiterated a Buy rating on Tvardi Therapeutics today and set a price target of $12.00. The company’s shares closed last Tuesday at $3.98, close to its 52-week low of $2.71.

According to TipRanks.com, Chatterjee is a top 100 analyst with an average return of 53.2% and a 76.0% success rate. Chatterjee covers the Healthcare sector, focusing on stocks such as Contineum Therapeutics, Inc. Class A, Sagimet Biosciences, Inc. Class A, and Sionna Therapeutics, Inc. ;'>

Currently, the analyst consensus on Tvardi Therapeutics is a Moderate Buy with an average price target of $8.60, implying an 116.6% upside from current levels. In a report issued on May 8, BTIG also maintained a Buy rating on the stock with a $15.00 price target.

Organigram Global (OGI)

In a report released today, Aaron Grey from Alliance Global Partners maintained a Buy rating on Organigram Global, with a price target of C$4.00. The company’s shares closed last Tuesday at $1.11, close to its 52-week low of $0.96.

According to TipRanks.com, Grey is ranked 0 out of 5 stars with an average return of -4.9% and a 34.9% success rate. Grey covers the Consumer Goods sector, focusing on stocks such as Village Farms International, Turning Point Brands, and Natural Grocers. ;'>

Currently, the analyst consensus on Organigram Global is a Strong Buy with an average price target of $2.69.

Read More on LEGN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).